08:00 , Jan 25, 2010 |  BC Week In Review  |  Company News

Biovel, Ranbaxy deal

Ranbaxy will acquire Biovel for an undisclosed sum. Biovel develops and markets biogenerics and biopharmaceuticals, including Typhoid Vi antigen vaccine against typhoid and Hib conjugate vaccine against Haemophilus influenzae, which are approved in India. Ranbaxy...
07:00 , May 21, 2007 |  BC Week In Review  |  Company News

Biovel Life Sciences Pte. Ltd., Dow Chemical deal

Biovel received non-exclusive rights to use DOW subsidiary Dowpharma's Pseudomonas-based Pfenex Expression Technology to manufacture human growth hormone (HGH). Dowpharma will receive an undisclosed upfront fee and is eligible for maintenance fees and milestones, plus...